Stockhub

Public Joint-Stock Company "Pharmsynthez"

Revision as of 17:09, 25 September 2022 by 95.149.241.133 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Public Joint-Stock Company ‘Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez' has...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

Public Joint-Stock Company ‘Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company ‘Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=Public_Joint-Stock_Company_%22Pharmsynthez%22&oldid=95420"